Stock 4576 D. WESTERN THERAPEUTICS INSTITUTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights D. Western Therapeutics Institute, Inc.

Equities

4576

JP3548740004

Market Closed - Japan Exchange
Other stock markets
 07:00:00 04/06/2024 BST 		5-day change 1st Jan Change
90 JPY +1.12% Intraday chart for D. Western Therapeutics Institute, Inc. -1.10% -36.17%
05-17 D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.37 million in funding CI
02-14 D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024
CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023
CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024
CI
D. Western Therapeutics Institute, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021
CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the First Quarter Ended March 31, 2021
CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the Year Ended December 31, 2020
CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020
CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2020
CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Sis Months Ended June 30, 2020
CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2020
CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Earnings Guidance for the Full Year Ending December 31, 2020
CI
Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute
CI
D. Western Therapeutics Institute, Inc. completed the acquisition of ophthalmic surgical adjuvant business from Healios K.K..
CI
D. Western Therapeutics Institute, Inc. agreed to acquire ophthalmic surgical adjuvant business from Healios K.K. for ¥1.3 billion.
CI
D.Western Therapeutics Institute, Inc. Launches Drug for Treating Glaucoma and Ocular Hypertension
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4576 Stock
  4. News D. Western Therapeutics Institute, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW